{"filings":[{"id":93853,"accession_number":"0001104659-26-056733","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theravance Q1 net loss narrows to $4.9M; YUPELRI revenue up 15%; all generic litigation settled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["YUPELRI collaboration revenue of $17.7M, up 15% YoY; implied 35% share of net sales $21.9M (+7%).","Net loss $4.9M vs. $13.6M YoY; Non-GAAP net income from operations $0.6M vs. loss of $8.6M.","Operating expenses down ~20% YoY (ex-restructuring); restructuring on track for ~60% reduction by Q3 2026.","All Hatch-Waxman YUPELRI litigation resolved; settlement with Mankind Pharma sets licensed launch date April 23, 2039.","Cash $395M, no debt; Strategic Review Committee evaluating sale or other value-maximizing alternatives."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":17699000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105803,"accession_number":"0001104659-26-036870","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Theravance settles YUPELRI patent suit; generic license start April 23, 2039","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement with Mankind Pharma resolves Hatch-Waxman litigation over YUPELRI (revefenacin) ANDA.","Royalty-free license granted for generic version on or after April 23, 2039, subject to customary exceptions.","All pending Hatch-Waxman litigation relating to YUPELRI now resolved; settlement subject to DOJ/FTC review.","Involves patents 11,484,531, 12,048,692 and 12,285,417; parties include Theravance subsidiaries and Mylan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105802,"accession_number":"0001104659-26-031795","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theravance reports Q4/FY2025 financials; restructuring after Phase 3 failure; strategic review ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4/FY2025: YUPELRI net sales $266.6M (+12% YoY); triggered $25M milestone.","TRELEGY net sales $3.9B (+12% YoY) triggered $50M milestone; confident in $100M 2026 milestone.","Restructuring after failed Phase 3 CYPRESS study; expects $60-70M annualized cash savings starting Q3 2026.","Cash ~$400M at end Q1 2026; no debt.","Strategic Review Committee accelerating evaluation of alternatives including potential sale of company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105801,"accession_number":"0001104659-26-022572","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["2.02","2.05","7.01","9.01"],"status":"ready","headline":"Theravance Biopharma Phase 3 CYPRESS study fails; plans 50% workforce cut and strategic review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 CYPRESS study of ampreloxetine for nOH in MSA did not meet primary endpoint (OHSA composite); program halted.","Organizational restructuring to reduce cost base ~60% (~$70M) and impact ~50% of workforce; R&D wound down, G&A cut ~50%.","Board's Strategic Review Committee accelerating evaluation of alternatives including a sale of the company.","Preliminary cash $326.5M at Q4 2025; expected ~$400M at Q1 2026 after $25M YUPELRI and $50M TRELEGY milestones received.","YUPELRI FY2025 net sales $266.6M (+12% YoY); company expects ~$60-70M annualized cash flow from restructuring and YUPELRI."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105800,"accession_number":"0001104659-26-002726","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Theravance Biopharma holds investor meetings with January 2026 corporate slide deck; no new financials or guidance","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Management team conducting one-on-one meetings with analysts and investors in San Francisco from Jan 12-15, 2026.","Slide deck furnished as Exhibit 99.1 contains corporate overview but no material new information beyond prior disclosures.","Filing under Regulation FD; no financial updates, pipeline changes, or guidance adjustments disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122085,"accession_number":"0001104659-25-119032","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Theravance holds ampreloxetine KOL event; AGM set for June 12, 2026","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Virtual KOL investor event for ampreloxetine held Dec. 8, 2025; slide deck furnished as exhibit.","2026 Annual General Meeting scheduled for June 12, 2026 in Dublin, Ireland.","Proxy materials will be filed with SEC and made available to shareholders prior to the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122084,"accession_number":"0001104659-25-109146","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theravance Biopharma Q3 2025: YUPELRI net sales hit all-time high $71.4M, achieves non-GAAP breakeven","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["YUPELRI net sales all-time high $71.4M (15% YoY); Viatris collaboration revenue $20M (+19%).","Non-GAAP net income from ops $2.3M (vs -$2.9M); GAAP net income $3.6M (includes $6.5M tax benefit).","Phase 3 CYPRESS of ampreloxetine (MSA-nOH): open-label done; topline data Q1 2026.","Cash $333M, no debt; TRELEGY YTD sales on track for $50M milestone in 2025.","Company achieves non-GAAP breakeven, underscoring financial discipline."],"consensus_eps_estimate":null,"consensus_eps_actual":0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":61573000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138791,"accession_number":"0001104659-25-082048","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Theravance Biopharma completes Phase 3 enrollment for ampreloxetine in nOH due to MSA; topline Q1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrollment completed in open-label portion of pivotal Phase 3 CYPRESS study (NCT05696717) for nOH due to MSA.","Expected topline results in Q1 2026; if positive, plans for expedited NDA submission and priority FDA review.","Ampreloxetine has Orphan Drug Designation in the U.S.; addresses ~40,000 patients with symptomatic nOH due to MSA.","Primary endpoint is change in OHSA composite score from randomized-withdrawal baseline to Week 8."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138790,"accession_number":"0001104659-25-080470","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Theravance settles YUPELRI patent litigation with Cipla; generic launch date April 23, 2039","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Settlement resolves Hatch-Waxman patent litigation on YUPELRI (revefenacin) inhalation solution.","Cipla granted royalty-free license to market generic version in U.S. on or after April 23, 2039.","Settlement subject to review by U.S. DOJ and FTC as required by law.","Patent litigation remains pending against Mankind Pharma Ltd. and affiliates (another ANDA filer)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138789,"accession_number":"0001104659-25-076837","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theravance Biopharma Q2 net income $54.8M driven by $225M TRELEGY royalty sale; YUPELRI sales +22%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["YUPELRI net sales $66.3M (Viatris-recorded) up 22% YoY; Q2 implied 35% share $23.2M.","Completed sale of TRELEGY royalty interest to GSK for $225M; net gain of $75.1M.","Pivotal Phase 3 CYPRESS study enrollment nearing completion; top-line data ~6 months later.","Cash $339M, no debt; TRELEGY YTD sales on track for $50M milestone in 2025.","Non-GAAP net loss from operations improved to $4.2M from $6.3M YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":41583000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156245,"accession_number":"0001104659-25-062722","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Theravance Biopharma's YUPELRI approved by China's NMPA; $7.5M milestone triggered","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["China's NMPA approved YUPELRI (revefenacin) as first once-daily nebulized LAMA for COPD maintenance.","Approval triggers $7.5M milestone from Viatris, expected Q3 2025; eligible for up to $37.5M in sales milestones and 14-20% tiered royalties.","Viatris responsible for all development/commercialization; Theravance incurs no commercial costs in China.","Theravance cash $131M (Mar 31), plus $225M from TRELEGY royalty sale and up to $150M near-term TRELEGY milestones.","Theravance nearing completion of enrollment in open-label portion of CYPRESS study of ampreloxetine for nOH in MSA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156244,"accession_number":"0001104659-25-056996","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Theravance settles YUPELRI patent litigation with Eugia; generic launch set for 2039","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement resolves Hatch-Waxman litigation over YUPELRI (revefenacin) with Eugia (Aurobindo).","Eugia granted royalty-free license to market generic version on or after April 23, 2039.","Settlement subject to review by U.S. DOJ and FTC as required by law.","Patent litigation continues against two other ANDA filers: Cipla and Mankind Pharma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156243,"accession_number":"0001104659-25-055100","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["1.01","2.01","7.01","9.01"],"status":"ready","headline":"Theravance Biopharma sells remaining Trelegy royalty interest to GSK for $225M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sells outer-year Trelegy royalties to GSK for $225M cash; transaction closed May 30, 2025.","Retains right to up to $150M in milestones from Royalty Pharma on 2025/2026 net sales.","First outcome from Strategic Review Committee formed Nov 2024; board committed to returning excess capital.","Total potential lifetime value from Trelegy monetization now $1.525B including prior $1.1B upfront.","2025 financial guidance unchanged; company continues to focus on YUPELRI and ampreloxetine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156242,"accession_number":"0001104659-25-051050","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Theravance Biopharma holds 2025 annual meeting, elects directors, ratifies auditor, approves say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders elected Rick E. Winningham, Jeremy T. Grant, Susannah Gray, Donal O'Connor as Class II directors.","Ratification of Ernst & Young as auditor for FY2025 approved: 45,165,816 for, 578,070 against.","Advisory say-on-pay resolution approved: 30,154,992 for, 374,257 against, 9,536,311 abstain.","Quorum of 45,746,079 shares (91.5% outstanding) present at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156241,"accession_number":"0001104659-25-046137","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theravance Biopharma Q1 net loss $13.6M; YUPELRI sales up 6% to $58.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["YUPELRI net sales of $58.3M recognized by Viatris, up 6% vs Q1 2024; Theravance's implied 35% share $20.4M.","Net loss $13.6M vs $11.7M in Q1 2024; Non-GAAP net loss from ops $8.6M vs $4.5M.","Revenue $15.4M entirely from Viatris collaboration, up 6% YoY.","Cash $131M, no debt; reaffirming all financial guidance.","CYPRESS study open label enrollment nearing completion, final patient expected by late summer; top-line data ~6 months later."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":15388000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174705,"accession_number":"0001104659-25-017438","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theravance Biopharma reports record Q4 and full year 2024 financial results with YUPELRI and TRELEGY milestones","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["YUPELRI US net sales reached $66.7M in Q4 2024 and $238.6M for full year, up 10% and 8% year-over-year, driven by increased customer demand.","TRELEGY global net sales of $3.46B in FY 2024 triggered a $50M milestone from Royalty Pharma, received in February 2025.","Company ended Q4 2024 with $88M cash, and CYPRESS study on track to enroll final patient by mid-2025.","Q4 2024 total revenue was $18.8M from Viatris collaboration, with net loss of $15.5M and non-GAAP net loss of $2.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":64381000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191660,"accession_number":"0001104659-24-116774","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theravance Biopharma Q3 2024: YUPELRI sales record $62.2M (+7%); net loss widens; board forms strategic review","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $16.9M (Viatris collab); implied YUPELRI net sales $62.2M all-time high (7% YoY, 14% QoQ).","Net loss $12.7M vs $9.0M YoY; non-GAAP net loss from operations $2.9M vs $0.7M.","TRELEGY milestone: Q4 sales ~$260M needed for $25M payment, ~$610M for $50M; YTD sales $2.6B.","Board forms Strategic Review Committee to assess alternatives to unlock shareholder value.","CYPRESS (ampreloxetine) open-label enrollment on track for mid-2025 completion; data ~6 months later."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":45627000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208127,"accession_number":"0001104659-24-101816","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Theravance Biopharma settles YUPELRI patent litigation; Qilu generic entry delayed until April 2039","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Settlement resolves Hatch-Waxman patent litigation over YUPELRI (revefenacin) with Qilu.","Qilu granted royalty-free license to market generic revfenacin on or after April 23, 2039.","Settlement subject to review by U.S. DOJ and FTC as required by law.","Patent litigation against three other ANDA filers (Cipla, Eugia, Mankind) remains pending."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208126,"accession_number":"0001104659-24-098326","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Theravance Biopharma presents at H.C. Wainwright conference; no material financial updates in slide deck","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Management team to participate in fireside chat and one-on-one meetings at H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024.","Slide presentation furnished as Exhibit 99.1 contains no new financial guidance or operational data beyond prior disclosures.","Filing is a procedural Regulation FD disclosure for investor presentation; no earnings, M&A, or leadership changes announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208125,"accession_number":"0001104659-24-085826","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theravance Biopharma Q2 net loss $16.5M; YUPELRI net sales down 1%; CYPRESS enrollment delayed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 net loss of $16.5M vs $15.6M YoY; non-GAAP net loss from operations $6.3M.","Viatris collaboration revenue $14.3M, up 4% YoY; implied 35% share of YUPELRI net sales $19.1M (down 1%).","YUPELRI net sales (Viatris) $54.5M, down 1%; demand up 13% and hospital share hit all-time highs.","CYPRESS study: last patient enrollment now expected mid-2025; top-line data ~6 months later.","TRELEGY Q2 global net sales ~$1.1B (+40% YoY); up to $50M milestones achievable in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":28759000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225685,"accession_number":"0001104659-24-060536","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Theravance Biopharma Q1 2024: Viatris collab revenue up 39% to $14.5M; net loss narrows to $11.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Viatris collaboration revenue of $14.5M, up 39% YoY; implied 35% share of YUPELRI net sales $19.3M, up 18%.","Net loss of $11.7M narrowed from $22.1M YoY; non-GAAP net loss from operations $4.5M vs $14.9M.","YUPELRI total net sales $55.2M (by Viatris), +18% YoY; hospital doses sold up 31%.","Cash balance $100M; R&D expenses $9.0M down from $14.6M; SG&A $16.7M down from $19.2M.","Ampreloxetine CYPRESS enrollment continues; open-label enrollment expected H2 2024; KOL event May 23."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":14503000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225684,"accession_number":"0001104659-24-059338","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Theravance Biopharma shareholders elect three Class I directors, ratify EY, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Eran Broshy, James Kelly, Laurie Smaldone Alsup as Class I directors for three-year terms; votes for each exceeded 35 million.","Ratified Ernst & Young as independent auditor for FY 2024 with 39,257,982 for, 228,078 against.","Non-binding advisory resolution on named executive officer compensation passed with 35,205,714 for, 332,345 against.","Total shares voted at annual meeting: 39,493,689 (81.3% of outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244843,"accession_number":"0001104659-24-028809","cik":1583107,"company_name":"Theravance Biopharma, Inc.","ticker":"TBPH","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Theravance settles YUPELRI patent litigation with Lupin; generic launch delayed to April 23, 2039","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement grants Lupin a royalty-free, non-exclusive license to market generic revefenacin starting April 23, 2039.","The settlement resolves ongoing Hatch-Waxman litigation based on Lupin's ANDA for YUPELRI.","Patent litigation continues against three other ANDA filers: Cipla, Eugia Pharma, and Mankind Pharma.","Settlement is subject to review by the U.S. Department of Justice and the Federal Trade Commission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":837220816.8806887,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}